LFG
URGN icon

Larson Financial Group’s UroGen Pharma URGN Stock Holding History

Larson Financial Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.39K Buy
244
+104
+74% +$2.08K ﹤0.01% 2665
2025
Q4 		$3.28K Hold
140
– – ﹤0.01% 2635
2025
Q3 		$2.79K Buy
+140
New +$2.51K ﹤0.01% 2576

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Larson Financial Group's URGN Position: Q1 2026 in Review

Larson Financial Group increased its UroGen Pharma (URGN) stake by 74% in Q1 2026, buying an estimated $2.08K and bringing the position to 244 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Larson Financial Group first reported a position in URGN in Q3 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Larson Financial Group held 244 shares of UroGen Pharma worth $4.39K as of Q1 2026.
  • Larson Financial Group bought 104 UroGen Pharma shares in Q1 2026, an estimated $2.08K.
  • UroGen Pharma made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2665 holding.
  • Larson Financial Group first reported a position in UroGen Pharma in Q3 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.